Pride month is not only a time to celebrate and honor Sana’s LGBTQIA+ employees and community, but also a time to acknowledge that there is still more work to be done to support equal rights. At Sana, we aspire to change the possible for patients, regardless of gender, identity, or sexual orientation. #Pride #Inclusivity #Kindness #LGBTQIA #DiversityMatters
Sana Biotechnology, Inc.
Biotechnology Research
Seattle, Washington 37,969 followers
Focused on creating and delivering engineered cells as medicines for patients
About us
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.
- Website
-
http://sana.com
External link for Sana Biotechnology, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Seattle, Washington
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
Get directions
188 E Blaine St
Suite 400
Seattle, Washington 98102, US
-
Get directions
1 Tower Pl
Suite 500
South San Francisco, California 94080, US
-
Get directions
300 Technology Sq
Suite 700
Cambridge, Massachusetts 02139, US
Employees at Sana Biotechnology, Inc.
Updates
-
We’re excited to sponsor the Federation of American Societies for Experimental Biology (FASEB)’s Genome Engineering: Research and Applications conference taking place June 16-20, 2024, in Rome, Italy. The conference will focus on groundbreaking research, innovative tools, and cutting-edge technologies in genome and epigenome editing. The Sana team eagerly anticipates connecting with peers and staying at the forefront of industry advancements. Learn more about the conference here: https://lnkd.in/gzHqfTXB hashtag #GENESRC
-
-
Steve Harr, MD, Sana’s President and CEO, will discuss the latest updates from Sana in a fireside chat at the Goldman Sachs 45th Annual Healthcare Conference on Monday, June 10, 2024 at 2:40 p.m. ET. Listen to the live or archived discussion here: https://lnkd.in/gFnFMcUD #Sanabiotechnology #Cellengineering #CellTherapy
-
Today, we honor the strength and resilience of those who have faced cancer. At Sana, we are dedicated to developing cures for patients with cancer and other serious diseases. Together, we celebrate National Cancer Survivor's Day and commit to a future of hope and healing. #CancerSurvivorsDay #LifeBeyondCancer
-
-
We are pleased to share that preclinical data demonstrating that healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice were published and featured as the May 2024 cover story in Nature Biotechnology. These data establish additional proof-of-concept for the development of SC379, Sana’s pluripotent stem cell-derived GPC product candidate, as a potential therapy to deliver healthy allogeneic GPCs to patients with certain central nervous system disorders. Learn more in the full press release here: https://lnkd.in/gbyXCqjN
-
-
At Sana, we are dedicated to developing cures for patients with cancer and other serious diseases. This #CancerResearchMonth, join us in raising awareness and supporting the ongoing efforts that continue to pave the way for new cancer treatments. Learn how you can join the fight against cancer here: https://lnkd.in/d6QV2xz #ResearchSavesLive #NCRM24
Get Involved
https://www.aacr.org
-
Steve Harr, MD, Sana’s President and CEO, will discuss the latest updates from Sana in a fireside chat at the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 3:00 p.m. PT. Listen to the live or archived discussion here: https://lnkd.in/gFnFMcUD #Sanabiotechnology #Cellengineering #CellTherapy
Events and Presentations | Sana Biotechnology, Inc
ir.sana.com
-
Sana CFO Nate Hardy will discuss the latest updates from Sana in a fireside chat at the Citizens JMP Conference on Monday, May 13, 2024 at 11:30 a.m. ET. Listen to the live or archived discussion here: https://lnkd.in/gFnFMcUD #Sanabiotechnology #Cellengineering #CellTherapy
Events and Presentations | Sana Biotechnology, Inc
ir.sana.com
-
We’re excited to join #LupusTherapeutics and Lupus Research Alliance as sponsors of the fourth annual Lupus Clinical Investigators Network (LuCIN) Community Meeting. The annual meeting brings together clinical investigators, study coordinators, people with lupus and industry partners to participate in discussions around critical research initiatives and the latest approaches in lupus treatment. To learn more about LuCIN visit https://bit.ly/LuCIN2024. #LupusClinicalResearch #LuCINCommunity #ProudSponsor #LupusAwarenessMonth
Home - Lupus Therapeutics
https://lupustherapeutics.org